慢性呼吸系统疾病患者拔管后间歇无创通气:多中心随机对照试验(VHYPER)
本研究为前瞻性随机对照多中心试验,纳入144例耐受自主呼吸试验的慢性呼吸系统疾病机械通气患者,拔管后随机分为无创通气组(n=72,拔管后48小时内采用间歇无创通气)和常规氧疗组(n=72)。主要终点为拔管后48小时内呼吸衰竭,无创通气组6例(8.5%) vs 常规氧疗组20例(27.8%),p=0.0016。再插管率两组无显著差异(8.5% vs 18.1%,p=0.09),ICU死亡率和90天死亡率亦无显著差异(p=0.28和p=0.33)。常规氧疗组中位ICU住院时间更短(3天 vs 4天,p=0.008)。自主呼吸试验期间高碳酸血症患者拔管后呼吸衰竭风险升高(调整OR=4.56,95%CI 1.59-14.00,p=0.006)。
要点
- 慢性呼吸系统疾病患者拔管后48小时内间歇无创通气较常规氧疗降低呼吸衰竭发生率(8.5% vs 27.8%,p=0.0016)。
- 无创通气未显著降低再插管率(8.5% vs 18.1%,p=0.09)及ICU死亡率、90天死亡率(p=0.28和p=0.33)。
- 常规氧疗组中位ICU住院时间更短(3天 vs 4天,p=0.008)。
- 自主呼吸试验期间高碳酸血症患者拔管后呼吸衰竭风险升高(调整OR=4.56,95%CI 1.59-14.00,p=0.006)。
- 该研究支持对慢性呼吸系统疾病患者拔管后早期使用间歇无创通气以降低呼吸衰竭风险。
适用人群与场景
- 纳入:慢性呼吸系统疾病、机械通气并耐受自主呼吸试验的患者,共144例。
- 场景:ICU拔管后48小时内。
诊断标准与关键阈值
- 自主呼吸试验期间高碳酸血症:拔管后呼吸衰竭风险调整OR=4.56(95%CI 1.59-14.00,p=0.006),再插管调整OR=3.60(95%CI 1.07-13.31,p=0.04)。
处置流程与药物剂量
- 无创通气组:拔管后48小时内采用间歇无创通气方式给予NIV。
- 常规氧疗组:拔管后给予常规氧疗。
红旗征与不能漏的情况
- 自主呼吸试验期间出现高碳酸血症的患者拔管后呼吸衰竭风险升高(调整OR=4.56,95%CI 1.59-14.00)。
研究设计与关键结果
- 研究类型:前瞻性随机对照多中心试验;样本量144例(无创通气组n=72,常规氧疗组n=72);人群:慢性呼吸系统疾病机械通气耐受自主呼吸试验患者;干预:拔管后48小时内间歇无创通气 vs 常规氧疗;主要终点:拔管后48小时内呼吸衰竭,无创通气组6例(8.5%) vs 常规氧疗组20例(27.8%),p=0.0016。
- 再插管:无创通气组6例(8.5%) vs 常规氧疗组13例(18.1%),p=0.09。
- ICU死亡率:两组无显著差异(p=0.28);90天死亡率:两组无显著差异(p=0.33)。
- 中位ICU住院时间:常规氧疗组3天(IQR 2-6) vs 无创通气组4天(IQR 2-7),p=0.008。
- 自主呼吸试验期间高碳酸血症:拔管后呼吸衰竭调整OR=4.56(95%CI 1.59-14.00,p=0.006),再插管调整OR=3.60(95%CI 1.07-13.31,p=0.04)。
证据类型、等级与局限
- 证据类型:前瞻性随机对照多中心试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对慢性呼吸系统疾病机械通气患者,拔管后48小时内采用间歇无创通气可降低呼吸衰竭风险,但再插管率、ICU死亡率和90天死亡率无显著差异,且无创通气组中位ICU住院时间更长(4天 vs 3天)。
- 自主呼吸试验期间高碳酸血症患者拔管后呼吸衰竭和再插管风险更高,可能需要加强监测。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
PURPOSE: Early noninvasive ventilation (NIV) after extubation decreases the risk of respiratory failure and lowers 90-day mortality in patients with hypercapnia. Patients with chronic respiratory disease are at risk of extubation failure. Therefore, it could be useful to determine the role of NIV with a discontinuous approach, not limited to patients with hypercapnia. We assessed the efficacy of early NIV in decreasing respiratory failure after extubation in patients with chronic respiratory disorders.
METHODS: A prospective randomized controlled multicenter study was conducted. We enrolled 144 mechanically ventilated patients with chronic respiratory disorders who tolerated a spontaneous breathing trial. Patients were randomly allocated after extubation to receive either NIV (NIV group, n = 72), performed with a discontinuous approach, for the first 48 h, or conventional oxygen treatment (usual care group, n = 72). The primary endpoint was decreased respiratory failure within 48 h after extubation. Analysis was by intention to treat. This trial was registered with ClinicalTrials.gov (NCT01047852).
RESULTS: Respiratory failure after extubation was less frequent in the NIV group: 6 (8.5%) versus 20 (27.8%); p = 0.0016. Six patients (8.5%) in the NIV group versus 13 (18.1%) in the usual care group were reintubated; p = 0.09. Intensive care unit (ICU) mortality and 90-day mortality did not differ significantly between the two groups (p = 0.28 and p = 0.33, respectively). Median postrandomization ICU length of stay was lower in the usual care group: 3 days (IQR 2-6) versus 4 days (IQR 2-7; p = 0.008). Patients with hypercapnia during a spontaneous breathing trial were at risk of developing postextubation respiratory failure [adjusted odds ratio (95% CI) = 4.56 (1.59-14.00); p = 0.006] and being intubated [adjusted odds ratio (95% CI) = 3.60 (1.07-13.31); p = 0.04].
CONCLUSIONS: Early NIV performed following a sequential protocol for the first 48 h after extubation decreased the risk of respiratory failure in patients with chronic respiratory disorders. Reintubation and mortality did not differ between NIV and conventional oxygen therapy.
参考来源
- Vargas F, Clavel M, Sanchez-Verlan P, et al. Intermittent noninvasive ventilation after extubation in patients with chronic respiratory disorders: a multicenter randomized controlled trial (VHYPER). Intensive Care Med. 2017. PMID: 28393258. doi:10.1007/s00134-017-4785-1
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。